Piramal Snaps Up Peptide API Specialist Hemmo
Bolsters CDMO Business In Deal Worth More Than $100m
Piramal has announced a $106m deal to take full ownership of peptide API specialist Hemmo Pharmaceuticals, expanding its CDMO capabilities.
You may also be interested in...
Kyorin, Eisai build on earlier OAB deal to team on vibegron. Plus deals involving Piramal/Hemmo, ImmuneOncia/3D Medicines, Kyowa Kirin/Cerecor, Simcere/Kazia, Nippon Shinyaku/Menarini, Tarsus/LianBio
Private equity group Carlyle has acquired 20% of Piramal's pharma business for close to $500m, with the Indian group expected to use the capital raise to bolster organic and inorganic growth and deleverage the balance sheet.
Action is needed from both the UK government and the European Commission to prevent a collapse of Northern Ireland’s generics market, according to the BGMA.